nCounter® Metabolic Pathways Panel

Helping Your Research

Quantify the expression of hundreds of genes involved in core metabolic processes and immunometabolism for human or mouse samples in a reliable, simple, and robust way using the nCounter Metabolic Pathways Panel. Understand the complex mechanisms behind metabolic adaptation, metabolic switching, metabolic alterations, and study changes in mitochondrial respiration and glycolysis.

The Metabolic Pathways Panel helps advance efforts towards novel therapeutic targets that take advantage of altered metabolism in cancer and other diseases. Get results in less than 24 hours from multiple sample types with a workflow that maximizes insight and minimizes turnaround time:

Quantify the presence and relative abundance of 14 different immune cell types for immunometabolism studies
Bypass RT and amplification by direct detection, yielding highly reproducible data
Process your samples with < 30 minutes hands-on time and get results in < 24 hours
Receive publication-ready figures with off-the-shelf data analysis with nSolver™ Data Analysis Software

How It Works

The underlying molecular mechanisms behind alterations in metabolic pathways, signaling pathways, and cell stress can now be fully elucidated, giving you a complementary tool to traditional metabolite assays for profiling metabolic checkpoints and potential therapeutic targets.

Directly profile 768 genes in human or mouse across 34 annotated pathways involved in five important themes for metabolism research:

01:

Biosynthesis and Anabolic Pathways

02:

Nutrient Capture and Catabolic Pathways

03:

Cell Stress

04:

Metabolic Signaling

05:

Transcriptional Regulation

Publications

View All Publications

Spatial transcriptomics and proteomics technologies for deconvoluting the tumor microenvironment.

The tumor microenvironment (TME) harbors heterogeneous contents and plays critical roles in tumorigenesis, metastasis, and drug resistance. Therefore, the deconvolution of the TME becomes increasingly essential to every aspect of cancer research and treatment.

Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids.

Tumors evade immune surveillance by expressing Programmed Death-Ligand 1 (PD-L1), subsequently inhibiting CD8+ cytotoxic T lymphocyte function. Response of gastric cancer to immunotherapy is relatively low.

Models that combine transcriptomic with spatial protein information exceed the predictive value for either single modality.

Immunotherapy has reshaped the field of cancer therapeutics but the population that benefits are small in many tumor types, warranting a companion diagnostic test. While immunohistochemistry (IHC) for programmed death-ligand 1 (PD-L1) or mismatch repair (MMR) and polymerase chain reaction (PCR) for microsatellite instability (MSI) are the only approved companion diagnostics others are under consideration.